tereotactic body radiation therapy (SBRT) has rapidly been adopted into clinical practice as an option for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) based on reports of excellent outcomes, often with local tumor control Ն90%, from centers in North America, Europe, and Asia. 1 Although data for metastatic lung tumors are less robust, experience supporting SBRT as a viable alternative to surgical resection in this patient population is growing, and Siva et al. 2 provide a comprehensive review of SBRT for pulmonary (oligo) metastases in this issue of the journal. They conclude that SBRT seems both effective and safe in the metastatic setting as a 2-year local tumor control approached 80%, whereas severe toxicity was observed in less than 5% of patients.
chemotherapy have been linked to toxicity. 1 It should be acknowledged that assigning a direct cause for pulmonary toxicity in a population with baseline pulmonary dysfunction is challenging at best, with some suggesting that aggravation of dyspnea after SBRT reflects exacerbations of underlying pulmonary disease rather than treatment-related toxicity. 7 Moreover, fatal toxicity has also been observed after alternative treatment approaches for this population including sublobar resection and radiofrequency ablation. 8, 9 Although the potential toxic effects of SBRT for centrally located lesions have been emphasized, several recent reports raise concerns about the treatment of very peripheral lesions that may be in proximity to the rib and chest wall. In this setting, unexpected high rates of skin, rib, and brachial plexus toxicity after SBRT have now been reported even from institutions with substantial SBRT experience and expertise. 10 -13 In fact, on the RTOG 0236 study, six patients were classified as having adverse events that were not classified prospectively as protocol specified (as they were not likely anticipated when the trial opened in 2004), including three patients with grade 3 soft tissue (skin or rib) treatmentrelated complications. 3 Given these observations, specific dose constraints for SBRT regimens have been updated by the RTOG and the National Comprehensive Cancer Network has published SBRT guidelines for NSCLC. 14, 15 In this issue of the journal, Devisetty and Salama 16 report two cases of severe lung cavitation that developed during the course of image-guided SBRT for peripheral NSCLC. Although these changes were not associated with clinical sequelae, the authors raised concerns given experience correlating cavitation with fatal bleeding in patients receiving the antivascular endothelial growth factor receptor bevacizumab with chemotherapy in advanced NCSLC. 17 Interestingly, fatal toxicity (from fistula formation) has also been reported after administration of bevacizumab in patients with a history of thoracic radiotherapy. 18 Although both patients in this report had medical comorbidities including vascular disease and diabetes mellitus, similar factors are present in the majority of patients with stage I NSCLC deemed ineligible for lobectomy. As such, it is not clear which factors may have precipitated these unique radiographic changes.
In fact, it is perhaps most surprising that there have been relatively few reports of unusual and severe reactions after the extreme doses delivered with SBRT. Although the comfort level has risen with SBRT regimens, there is still much to learn regarding the biology of very large radiotherapy fractions and potential complications of therapy. As opposed to conventionally fractionated radiotherapy, which presumably follows classic radiobiologic principles predicting preferential tumor cell killing and relative protection of normal structures, SBRT uses doses that are theorized to have a direct ablative effect on both tumors and surrounding tissue. Therefore, the use of advanced technology such as (respiratory) motion management and image guidance are critical to ensuring that radiation dose is applied only to the intended target.
The development of SBRT for early-stage NSCLC is a great success story for the field of radiation oncology in that we can now offer patients a high-tech, noninvasive treatment that can be completed in a minimum of visits with a high expectation of success. For the most part, the question has become: Which medically inoperable patients should not receive SBRT? Nevertheless, there remains much work to be done in identifying factors that place patients at high risk for severe toxicity, and this may be particularly challenging given marked variation in SBRT fractionation, dose, technique, target determination, and dose calculation algorithm.
And although outcomes for SBRT have been impressive, alternative treatments options also seem quite promising. For example, single institution series have reported excellent local tumor control after sublobar resection and brachytherapy in high-risk T1N0 NSCLC, and the American College of Surgeons Oncology Group recently completed a phase III study assessing the addition of I-125 brachytherapy to sublobar resection in this population. 19 At this time, a phase III trial comparing sublobar resection and SBRT is being considered by the RTOG and American College of Surgeons Oncology Group. Accelerated hypofractionated radiation regimens that preserve some degree of fractionation may also have merit. The Cancer and Leukemia Group B recently reported mature results of accelerated conformal radiotherapy to a dose of 70 Gy for node-negative NSCLC up to 4 cm. With median follow-up of 53 months, only three local failures were identified in 39 patients, whereas grade 3 toxic effects were observed in only two patients. 20 An additional prospective trial from the NCI Canada testing a regimen of 60 Gy in 15 fractions more than 3 weeks for peripheral NSCLC lesions up to 5 cm completed accrual and results should be reported in the near future. 21 Advances in the past decade have radically changed expectations for patients with medically inoperable earlystage NSCLC. Phase III comparative studies will be necessary to provide definitive information regarding the therapeutic ratio of SBRT and alternative treatment options. In the meantime, meticulous radiation treatment planning and delivery is essential for centers performing SBRT, and vigilance is required in carefully monitoring and reporting patient outcomes.
